Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid

Pathology

Volumn 40, Issue 5, 2008, Pages 475-480

  Cvejic, Dubravka ^a   Selemetjev, Sonja ^a   Savin, Svetlana ^a   Paunovic, Ivan ^b   Petrovic, Ivana ^a   Tatic, Svetislav ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Bax; Bcl 2; Immunohistochemistry; p53; Papillary carcinoma; Papillary microcarcinoma; PCNA; Thyroid

Indexed keywords

CYCLINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHILD; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEWBORN; PAPILLARY CARCINOMA; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA;

EID: 46749094334     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802026989     Document Type: Article

References (37)

1. Li Volsi VA. Surgical Pathology of the Thyroid. Philadelphia: Saunders, 1990.
2. rd Series. Washington, DC: Armed Forces Institute of Pathology, 1992; 161-82.
3. Mizukami Y, Michigishi T, Nonomura A, Noguchi M, Nakamura T. Thyroid carcinoma: clinical, pathologic correlations. Crit Rev Oncol Hematol 1995; 18: 67-102.
4. Mazzaferri EL, Jhiang S. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-28.
5. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from Surveillance, Epidemiology and END Results (SEER) program 1973-1991. Cancer 1997; 79: 564-73.
6. Albores-Saavedra JA, Jianhua W. The many faces and mimics of papillary thyroid carcinomas. Endocrine Pathol 2006; 17: 1-18.
7. Fleming ID, Cooper JS, Henson DE. Thyroid gland. In: American Joint Committee on Cancer. Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997; 59-64.
8. Shah JP, Kian K, Forastiere A, et al. American Joint Committee on Cancer. Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002; 77-87.
9. Roti E, Rossi R, Transforini G, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006; 91: 2171-8.
10. Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathol 2003; 14: 183-92.
11. Pelizzo MR, Boschin IM, Toniato A, et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 2006; 32: 1144-8.
12. Baloch ZW, Li Volsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol 2006; 13: 69-75.
13. Rubin LI, Philpott Ki, Brooks SF. The cell cycle and cell death. Curr Biol 2003; 3: 391-4.
14. Mikulski SM. Pathogenesis of cancer in view of mutually opposing apoptotic and anti-apoptotic growth signals. Int J Oncology 1994; 4: 1257-63.
15. Mathew R, White E. FLIPping the balance between apoptosis and proliferation in thyroid cancer. Clin Canc Res 2006; 12: 3648-51.
16. Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-49.
17. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
18. Fridman JS, Lowe W. Control of apoptosis by p53. Oncogene 2003; 22: 9030-40.
19. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
20. LiVolsi VA, Albores-Saavedra J, Asa S, et al. Papillary carcinoma. In: DeLellis RA, Lloyd RV, Heitz U, Eng C, editors. Pathology and Genetics. Tumours of Endocrine Organs. Lyon: World Health Organization, IARC Press, 2004.
21. Horie S, Maeta H, Endo K, Ueta T, Takashima K, Terada T. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: correlations with clinicopathological features. Pathol Int 2001; 51: 11-5.
22. Preto A, Reis-Filho JS, Ricardo S, Soares P. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract 2002; 198: 449-54.
23. Gross A, McDonell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-911.
24. Pilotti S, Collini P, Rilke F, Cattoreti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994; 172: 337-42.
25. Branet F, Brousset P, Krajewski S, et al. Expression of the cell death-inducing gene Bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab 1996; 81: 2726-30.
26. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. Bcl-2, p53 and proliferating cell nuclear antigen expression are related to the degree of differentiation in thyroid carcinomas. Br J Cancer 1996; 73: 139-43.
27. Manetto V, Lorenzini R, Cordon-Cardo C, et al. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Arch 1997; 430: 125-30.
28. Moore D, Ohene-Fianko D, Garcia B, Chakrabarti S. Apoptosis in thyroid neoplasms: relationship with p53 and Bcl-2 expression. Histopathology 1988; 32: 35-42.
29. Mitselou A, Peschos D, Dallas P, Charalabopoulos K, Agnantis NJ, Vougiouklakis T. Immunohistochemical analysis of expression of Bcl-2 protein in papillary carcinomas and papillary microcarcinomas of the thyroid gland. Exp Oncol 2004; 26: 282-6.
30. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of Bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg 2005; 105: 644-8.
31. Ito Y, Uruno T, Takamura Y, et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 2005; 68: 87-96.
32. Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C. Immunohistochemical expression of Bcl-2, ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biol 2005; 26: 50-6.
33. Hermann S, Sturm I, Mrozek I, et al. Bax expression in benign and malignant thyroid tumours: dysregulation of wild type p53 is associated with a high Bax and p21 expression in thyroid carcinoma. Int J Cancer 2001; 92: 805-11.
34. Karlidag T, Cobanoglu B, Keles E, et al. Expression of Bax, p53 and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol 2007; 28: 31-6.
35. Sugitani I, Yanagisava A, Shimizu A, Kato M, Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World Surg 1998; 22: 731-7.
36. Chen B-K, Ohtsuki Y, Furihata M, et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999; 15: 893-8.
37. Corapcioglu D, Sak DS, Delibasi T, et al. Papillary microcarcinoma of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas. J Translat Med 2006; 4: 28-33.